McBride Marketing; Revocation of Registration, 35710-35711 [E6-9707]
Download as PDF
35710
Federal Register / Vol. 71, No. 119 / Wednesday, June 21, 2006 / Notices
Order
Accordingly, pursuant to the
authority vested in me by 21 U.S.C.
823(f) and 28 CFR 0.100(b) and 0.104(b),
I hereby order that Respondent’s
application for a DEA Certificate of
Registration be, and it hereby is, denied.
This order is effective July 21, 2006.
Dated: June 12, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6–9706 Filed 6–20–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
jlentini on PROD1PC65 with NOTICES
McBride Marketing; Revocation of
Registration
On October 13, 2004, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause proposing to revoke
McBride Marketing’s (Respondent) DEA
Certificate of Registration, 002748MMY,
as a distributor of List I chemicals and
to deny any pending applications for
renewal. As grounds for the action, the
Show Cause Order alleged that
Respondent’s continued registration
would be inconsistent with the public
interest. See 21 U.S.C. 824(a)(4).
Specifically, the Show Cause Order
alleged, inter alia, that Respondent did
not have adequate security to protect
List I chemical products from diversion,
that Respondent did not maintain
adequate sales records in accordance
with 21 CFR 1310.06, that Respondent
had product shortages, and that
Respondent had been acquiring and
distributing pseudoephedrine products
even though it was not registered to do
so.
The Show Cause Order was sent by
certified mail, return receipt requested,
to Respondent’s registered location and
receipt was acknowledged on October
20, 2004. Neither Respondent, its
owner, nor anyone else purporting to
represent it has responded. Because (1)
more than thirty days have passed since
the receipt of the Show Cause Order,
and (2) no request for a hearing has been
received, I conclude that Respondent
has waived its right to a hearing. See 21
CFR 1309.53(c). I therefore enter this
final order without a hearing based on
relevant material in the investigative file
and make the following findings.
Findings
Ephedrine and pseudoephedrine are
List I chemicals that while having
therapeutic uses, are easily extracted
VerDate Aug<31>2005
18:26 Jun 20, 2006
Jkt 208001
from lawful products and used in the
illicit manufacture of
methamphetamine, a schedule II
controlled substance. See 21 U.S.C.
802(34). As noted in numerous prior
DEA orders, ‘‘methamphetamine is an
extremely potent central nervous system
stimulant.’’ A–1 Distribution Wholesale,
70 FR 28573 (2005). Methamphetamine
abuse has destroyed lives and families,
ravaged communities, and created
serious environmental harms.
Methamphetamine abuse is an
especially serious problem in
Tennessee, the State in which
Respondent’s business is located. At the
time of the issuance of the Show Cause
Order, Tennessee led the Southeast in
clandestine lab seizures, accounting for
approximately 59% of these seizures
during the second quarter of 2004.
Moreover, in enacting the Meth-Free
Tennessee Act of 2005, the Tennessee
legislature found that as a result of these
seizures, ‘‘more than 700 children are
entering state custody each year.’’ 2005
Tennessee Laws Pub. Ch. 18 (Preamble).
Respondent is an unincorporated
firmed owned by Mr. Bobby McBride.
The firm, which is located at the
McBrides’ home in Parsons, Tennessee,
has held a DEA registration to distribute
ephedrine products since 1998.
Respondent has approximately 58
convenience store and gas stations
customers which purchase listed
chemical products. Although
Respondent also sells novelty items and
toys, listed chemicals account for 30%
of its business.
On February 26, 2004, two DEA
Diversion Investigators (DIs) visited
Respondent to conduct a regulatory
investigation. They met with Nancy
McBride, the owner’s wife and
Respondent’s bookkeeper, presented her
with their credentials and a notice of
inspection, and obtained Respondent’s
consent to the inspection.
During the inspection, the DIs
determined that Respondent stored
listed chemical products in two minivans. While the vans were kept locked
at all times, the vehicles did not have
alarm systems.
The DIs also conducted an inventory
and audit of Respondent’s ephedrine
products. In reviewing the records, the
DIs determined that while Respondent’s
sales records included the purchaser’s
name, product description and quantity,
the records did not contain the brand
name of the products, price, or the
customer’s address. Therefore, in
conducting the audit, the DIs were
required to group products together
based on package size. Moreover, while
Respondent’s owner claimed that he
conducted a physical inventory each
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
January, the record for January 2003
could not be found. The DIs thus used
the record for the January 2004
inventory as the beginning inventory
and conducted an accountability audit
covering the period of January 1, 2004,
through February 26, 2004.
The DI’s audit found shortages in both
the sixty-count bottles and six-count
package sizes. Notwithstanding the
relatively short period of the audit, 70
sixty-count bottles and 380 six-count
packages were unaccounted for. The DIs
also found in Respondent’s inventory
several pseudoephedrine products,
including four boxes of Tylenol Allergy
Sinus (with each box containing 50
sealed packets of one caplet), three
boxes of Aleve Cold and Sinus (with
each box containing 50 sealed packets of
two gel caps), and one box of Vick’s
Nyquil Liquicaps (with the box
containing 25 packets of two caplets).
Respondent, however, was not
registered to distribute pseudoephedrine
products. The DIs confirmed that
Respondent had been selling
pseudoephedrine products based on
their review of sales records and
interviews they conducted during
customer verification visits.
Discussion
21 U.S.C. 824(a) provides that a
registration to distribute List I chemical
may be suspended or revoked ‘‘upon a
finding that the registrant * * * has
committed such acts as would render
[its] registration under section 823 of
this title inconsistent with the public
interest as determined under [that]
section.’’ In making the public interest
determination, the Controlled
Substances Act requires the
consideration of the following factors:
(1) Maintenance by the [registrant] of
effective controls against diversion of listed
chemicals into other than legitimate
channels;
(2) Compliance by the [registrant] with
applicable Federal, State, and local law;
(3) Any prior conviction record of the
[registrant] under Federal or State laws
relating to controlled substances or to
chemicals controlled under Federal or State
law;
(4) Any past experience of the applicant in
the manufacture and distribution of
chemicals; and
(5) Such other factors as are relevant to and
consistent with the public health and safety.
Id. 823(h).
‘‘[T]hese factors are considered in the
disjunctive.’’ Joy’s Ideas, 70 FR 33195,
33197 (2005). I ‘‘may rely on any one or
combination of factors, and may give
each factor the weight [I] deem[]
appropriate in determining whether a
registration should be revoked or an
E:\FR\FM\21JNN1.SGM
21JNN1
Federal Register / Vol. 71, No. 119 / Wednesday, June 21, 2006 / Notices
application for a registration be denied.’’
Id. See also Energy Outlet, 64 FR 14,269
(1999). In this case, I have concluded
that factors one, two and five are
dispositive and support the revocation
of Respondent’s registration.
jlentini on PROD1PC65 with NOTICES
Factor One—Maintenance of Effective
Controls
I conclude that Respondent does not
maintain effective controls against
diversion. Respondent’s storage of its
List I chemical products in two minivans is clearly inadequate to protect
against diversion. DEA’s regulations
clearly contemplate that List 1
chemicals be stored in a secure premises
and not in motor vehicles unless in
transit. See 21 CFR 1309.71(b) (directing
DEA to consider ‘‘[t]he location of the
premises,’’ and ‘‘[t]he type of building
construction comprising the facility and
the general characteristics of the
building or buildings’’).
While the DIs were correct to note
that the vehicles did not have alarms,
even if Respondent’s vehicles had
alarms, they would not comply with the
regulations. A thief can steal a vehicle
in far less time than it takes to break into
a properly secured and alarmed
premises. Moreover, a thief stealing a
van holding listed chemicals does not
have to load the goods into the getaway
vehicle. Storage of listed chemicals in a
van plainly creates an unacceptable risk
of diversion.
The shortages that were found during
the audit further support the conclusion
that Respondent does not maintain
effective controls against diversion. The
shortages uncovered in the audit were
substantial given that the audit only
covered a period of two months. I need
not find that diversion was the cause of
the shortages to conclude that
Respondent does not maintain effective
controls against diversion.
Furthermore, Respondent’s sales
records did not contain the addresses of
its purchasers. Such information is
essential for DEA and local authorities
to effectively investigate whether
purchasers are conducting a legitimate
business or whether diversion is
occurring. I thus conclude that factor
one weighs heavily against
Respondent’s continued registration.
Factor 2—Compliance With Applicable
Law
As stated above, Respondent’s use of
mini-vans to store List I chemicals does
not comply with the physical security
regulations. Moreover, Respondent
failed to properly maintain sales records
because its invoices did not contain
product names and the addresses of the
purchasers. See 21 CFR 1310.03 and
VerDate Aug<31>2005
18:26 Jun 20, 2006
Jkt 208001
1310.06. Finally, Respondent engaged in
the distribution of pseudoephedrine
notwithstanding that its registration did
not give it authority to distribute the
chemical. See 21 CFR 1309.21(a)
(requiring registration ‘‘specific to the
List I chemicals to be handled’’). I thus
conclude that this factor weighs against
Respondent’s continued registration.
Factor 3—The Registrant’s Prior
Conviction Record
There is no evidence in the
investigative file establishing that
Respondent has been convicted of a
drug-related criminal offense. I thus find
that this factor weighs in favor of
continued registration. I conclude,
however, that this factor is entitled to
little weight as it is reasonable to expect
that DEA registrants not have a drugrelated criminal record.
Factor 4—The Registrant’s Past
Experience in Distributing List I
Chemicals
The record indicates that Respondent
has held a registration to distribute List
I chemicals since 1998. But in light of
the findings discussed above, it appears
that Respondent has been improperly
storing and distributing List I chemicals
in violation of DEA’s regulations for a
substantial period of time. I thus decline
to give Respondent’s experience any
weight in this determination.
Factor 5—Such Other Factors As Are
Relevant to and Consistent With the
Public Health and Safety
According to the investigative file,
Respondent distributes List 1 chemicals
solely to convenience stores and gas
stations in Western Tennessee, a State
which at the time these proceedings
were initiated had a severe problem
with methamphetamine abuse. As noted
above, Tennessee recently enacted the
Meth-Free Tennessee Act of 2005. See
also Joy’s Ideas, 70 FR at 33199. One of
the Act’s provisions requires that ‘‘any
product that contains any immediate
methamphetamine precursor may be
dispensed only by a licensed
pharmacy.’’ Tenn. St. § 39–17–431(a).
While the Act exempts from this
requirement those products containing
methamphetamine precursors ‘‘not in a
form that can be used in the
manufacture of methamphetamine,’’ id.
§ 39–17–431(b)(1), none of the
ephedrine products which Respondent
distributed under his DEA registration
are exempt. See id. § 39–17–431(b)(3)
(exempting gel capsules and liquid
preparations).
Respondent, however, does not have
any licensed pharmacies as customers,
and therefore, Respondent would
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
35711
violate state law were it to distribute
ephedrine products to its existing
customers. In prior orders, I have noted
the important role of the States in
combating the illicit manufacture of
methamphetamine. See, e.g., Joy’s Ideas,
70 FR at 33198 (discussing Oklahoma
and Tennessee legislation). Where, as
here, state efforts are fully consistent
with federal policy, it is appropriate to
give them due weight in determining
whether continuing a registration would
be consistent with public health and
safety.1 It would be manifestly
inconsistent with public health and
safety to continue Respondent’s
registration in light of the provisions of
Tennessee law. See id. at 33199. I
therefore conclude that factor five
weighs in favor of revocation. Having
considered all of the statutory factors, I
conclude that the continuance of
Respondent’s registration would be
inconsistent with the public interest.
Order
Accordingly, pursuant to the
authority vested in me by 21 U.S.C. 823
and 824, and 28 CFR 0.100(b) and 0.104,
I hereby order that DEA Certificate of
Registration, 002748MMY, issued to
McBride Marketing, be, and it hereby is,
revoked. I further order that any
pending applications for renewal or
modification of such registration be, and
they hereby are, denied. This order is
effective July 21, 2006.
Dated: June 12, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6–9707 Filed 6–20–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
Office of Juvenile Justice and
Delinquency Prevention
Agency Information Collection
Activities: Extension of a Currently
Approved Collection; Comment
Request
30-day notice of information
collection under review: National Crime
Victimization Survey (NCVS).
ACTION:
The U.S. Department of Justice (DOJ),
Office of Justice Programs (OJP) has
submitted the following information
1 I do not consider the relationship of Tennessee
law under factor two because at the time of the
investigation, the statute had not been enacted.
Moreover, there is no evidence in the investigative
file establishing that Respondent subsequently
violated state law.
E:\FR\FM\21JNN1.SGM
21JNN1
Agencies
[Federal Register Volume 71, Number 119 (Wednesday, June 21, 2006)]
[Notices]
[Pages 35710-35711]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9707]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
McBride Marketing; Revocation of Registration
On October 13, 2004, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration (DEA), issued an
Order to Show Cause proposing to revoke McBride Marketing's
(Respondent) DEA Certificate of Registration, 002748MMY, as a
distributor of List I chemicals and to deny any pending applications
for renewal. As grounds for the action, the Show Cause Order alleged
that Respondent's continued registration would be inconsistent with the
public interest. See 21 U.S.C. 824(a)(4). Specifically, the Show Cause
Order alleged, inter alia, that Respondent did not have adequate
security to protect List I chemical products from diversion, that
Respondent did not maintain adequate sales records in accordance with
21 CFR 1310.06, that Respondent had product shortages, and that
Respondent had been acquiring and distributing pseudoephedrine products
even though it was not registered to do so.
The Show Cause Order was sent by certified mail, return receipt
requested, to Respondent's registered location and receipt was
acknowledged on October 20, 2004. Neither Respondent, its owner, nor
anyone else purporting to represent it has responded. Because (1) more
than thirty days have passed since the receipt of the Show Cause Order,
and (2) no request for a hearing has been received, I conclude that
Respondent has waived its right to a hearing. See 21 CFR 1309.53(c). I
therefore enter this final order without a hearing based on relevant
material in the investigative file and make the following findings.
Findings
Ephedrine and pseudoephedrine are List I chemicals that while
having therapeutic uses, are easily extracted from lawful products and
used in the illicit manufacture of methamphetamine, a schedule II
controlled substance. See 21 U.S.C. 802(34). As noted in numerous prior
DEA orders, ``methamphetamine is an extremely potent central nervous
system stimulant.'' A-1 Distribution Wholesale, 70 FR 28573 (2005).
Methamphetamine abuse has destroyed lives and families, ravaged
communities, and created serious environmental harms.
Methamphetamine abuse is an especially serious problem in
Tennessee, the State in which Respondent's business is located. At the
time of the issuance of the Show Cause Order, Tennessee led the
Southeast in clandestine lab seizures, accounting for approximately 59%
of these seizures during the second quarter of 2004. Moreover, in
enacting the Meth-Free Tennessee Act of 2005, the Tennessee legislature
found that as a result of these seizures, ``more than 700 children are
entering state custody each year.'' 2005 Tennessee Laws Pub. Ch. 18
(Preamble).
Respondent is an unincorporated firmed owned by Mr. Bobby McBride.
The firm, which is located at the McBrides' home in Parsons, Tennessee,
has held a DEA registration to distribute ephedrine products since
1998. Respondent has approximately 58 convenience store and gas
stations customers which purchase listed chemical products. Although
Respondent also sells novelty items and toys, listed chemicals account
for 30% of its business.
On February 26, 2004, two DEA Diversion Investigators (DIs) visited
Respondent to conduct a regulatory investigation. They met with Nancy
McBride, the owner's wife and Respondent's bookkeeper, presented her
with their credentials and a notice of inspection, and obtained
Respondent's consent to the inspection.
During the inspection, the DIs determined that Respondent stored
listed chemical products in two mini-vans. While the vans were kept
locked at all times, the vehicles did not have alarm systems.
The DIs also conducted an inventory and audit of Respondent's
ephedrine products. In reviewing the records, the DIs determined that
while Respondent's sales records included the purchaser's name, product
description and quantity, the records did not contain the brand name of
the products, price, or the customer's address. Therefore, in
conducting the audit, the DIs were required to group products together
based on package size. Moreover, while Respondent's owner claimed that
he conducted a physical inventory each January, the record for January
2003 could not be found. The DIs thus used the record for the January
2004 inventory as the beginning inventory and conducted an
accountability audit covering the period of January 1, 2004, through
February 26, 2004.
The DI's audit found shortages in both the sixty-count bottles and
six-count package sizes. Notwithstanding the relatively short period of
the audit, 70 sixty-count bottles and 380 six-count packages were
unaccounted for. The DIs also found in Respondent's inventory several
pseudoephedrine products, including four boxes of Tylenol Allergy Sinus
(with each box containing 50 sealed packets of one caplet), three boxes
of Aleve Cold and Sinus (with each box containing 50 sealed packets of
two gel caps), and one box of Vick's Nyquil Liquicaps (with the box
containing 25 packets of two caplets).
Respondent, however, was not registered to distribute
pseudoephedrine products. The DIs confirmed that Respondent had been
selling pseudoephedrine products based on their review of sales records
and interviews they conducted during customer verification visits.
Discussion
21 U.S.C. 824(a) provides that a registration to distribute List I
chemical may be suspended or revoked ``upon a finding that the
registrant * * * has committed such acts as would render [its]
registration under section 823 of this title inconsistent with the
public interest as determined under [that] section.'' In making the
public interest determination, the Controlled Substances Act requires
the consideration of the following factors:
(1) Maintenance by the [registrant] of effective controls
against diversion of listed chemicals into other than legitimate
channels;
(2) Compliance by the [registrant] with applicable Federal,
State, and local law;
(3) Any prior conviction record of the [registrant] under
Federal or State laws relating to controlled substances or to
chemicals controlled under Federal or State law;
(4) Any past experience of the applicant in the manufacture and
distribution of chemicals; and
(5) Such other factors as are relevant to and consistent with
the public health and safety.
Id. 823(h).
``[T]hese factors are considered in the disjunctive.'' Joy's Ideas,
70 FR 33195, 33197 (2005). I ``may rely on any one or combination of
factors, and may give each factor the weight [I] deem[] appropriate in
determining whether a registration should be revoked or an
[[Page 35711]]
application for a registration be denied.'' Id. See also Energy Outlet,
64 FR 14,269 (1999). In this case, I have concluded that factors one,
two and five are dispositive and support the revocation of Respondent's
registration.
Factor One--Maintenance of Effective Controls
I conclude that Respondent does not maintain effective controls
against diversion. Respondent's storage of its List I chemical products
in two mini-vans is clearly inadequate to protect against diversion.
DEA's regulations clearly contemplate that List 1 chemicals be stored
in a secure premises and not in motor vehicles unless in transit. See
21 CFR 1309.71(b) (directing DEA to consider ``[t]he location of the
premises,'' and ``[t]he type of building construction comprising the
facility and the general characteristics of the building or
buildings'').
While the DIs were correct to note that the vehicles did not have
alarms, even if Respondent's vehicles had alarms, they would not comply
with the regulations. A thief can steal a vehicle in far less time than
it takes to break into a properly secured and alarmed premises.
Moreover, a thief stealing a van holding listed chemicals does not have
to load the goods into the getaway vehicle. Storage of listed chemicals
in a van plainly creates an unacceptable risk of diversion.
The shortages that were found during the audit further support the
conclusion that Respondent does not maintain effective controls against
diversion. The shortages uncovered in the audit were substantial given
that the audit only covered a period of two months. I need not find
that diversion was the cause of the shortages to conclude that
Respondent does not maintain effective controls against diversion.
Furthermore, Respondent's sales records did not contain the
addresses of its purchasers. Such information is essential for DEA and
local authorities to effectively investigate whether purchasers are
conducting a legitimate business or whether diversion is occurring. I
thus conclude that factor one weighs heavily against Respondent's
continued registration.
Factor 2--Compliance With Applicable Law
As stated above, Respondent's use of mini-vans to store List I
chemicals does not comply with the physical security regulations.
Moreover, Respondent failed to properly maintain sales records because
its invoices did not contain product names and the addresses of the
purchasers. See 21 CFR 1310.03 and 1310.06. Finally, Respondent engaged
in the distribution of pseudoephedrine notwithstanding that its
registration did not give it authority to distribute the chemical. See
21 CFR 1309.21(a) (requiring registration ``specific to the List I
chemicals to be handled''). I thus conclude that this factor weighs
against Respondent's continued registration.
Factor 3--The Registrant's Prior Conviction Record
There is no evidence in the investigative file establishing that
Respondent has been convicted of a drug-related criminal offense. I
thus find that this factor weighs in favor of continued registration. I
conclude, however, that this factor is entitled to little weight as it
is reasonable to expect that DEA registrants not have a drug-related
criminal record.
Factor 4--The Registrant's Past Experience in Distributing List I
Chemicals
The record indicates that Respondent has held a registration to
distribute List I chemicals since 1998. But in light of the findings
discussed above, it appears that Respondent has been improperly storing
and distributing List I chemicals in violation of DEA's regulations for
a substantial period of time. I thus decline to give Respondent's
experience any weight in this determination.
Factor 5--Such Other Factors As Are Relevant to and Consistent With the
Public Health and Safety
According to the investigative file, Respondent distributes List 1
chemicals solely to convenience stores and gas stations in Western
Tennessee, a State which at the time these proceedings were initiated
had a severe problem with methamphetamine abuse. As noted above,
Tennessee recently enacted the Meth-Free Tennessee Act of 2005. See
also Joy's Ideas, 70 FR at 33199. One of the Act's provisions requires
that ``any product that contains any immediate methamphetamine
precursor may be dispensed only by a licensed pharmacy.'' Tenn. St.
Sec. 39-17-431(a). While the Act exempts from this requirement those
products containing methamphetamine precursors ``not in a form that can
be used in the manufacture of methamphetamine,'' id. Sec. 39-17-
431(b)(1), none of the ephedrine products which Respondent distributed
under his DEA registration are exempt. See id. Sec. 39-17-431(b)(3)
(exempting gel capsules and liquid preparations).
Respondent, however, does not have any licensed pharmacies as
customers, and therefore, Respondent would violate state law were it to
distribute ephedrine products to its existing customers. In prior
orders, I have noted the important role of the States in combating the
illicit manufacture of methamphetamine. See, e.g., Joy's Ideas, 70 FR
at 33198 (discussing Oklahoma and Tennessee legislation). Where, as
here, state efforts are fully consistent with federal policy, it is
appropriate to give them due weight in determining whether continuing a
registration would be consistent with public health and safety.\1\ It
would be manifestly inconsistent with public health and safety to
continue Respondent's registration in light of the provisions of
Tennessee law. See id. at 33199. I therefore conclude that factor five
weighs in favor of revocation. Having considered all of the statutory
factors, I conclude that the continuance of Respondent's registration
would be inconsistent with the public interest.
---------------------------------------------------------------------------
\1\ I do not consider the relationship of Tennessee law under
factor two because at the time of the investigation, the statute had
not been enacted. Moreover, there is no evidence in the
investigative file establishing that Respondent subsequently
violated state law.
---------------------------------------------------------------------------
Order
Accordingly, pursuant to the authority vested in me by 21 U.S.C.
823 and 824, and 28 CFR 0.100(b) and 0.104, I hereby order that DEA
Certificate of Registration, 002748MMY, issued to McBride Marketing,
be, and it hereby is, revoked. I further order that any pending
applications for renewal or modification of such registration be, and
they hereby are, denied. This order is effective July 21, 2006.
Dated: June 12, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6-9707 Filed 6-20-06; 8:45 am]
BILLING CODE 4410-09-P